SeqOne, a French innovator in AI-driven genomic evaluation, right now introduced it has entered right into a definitive settlement to accumulate Congenica, the UK firm spun out of the Wellcome Sanger Institute.
The acquisition is ready to create the “largest international software program pure participant within the genomics house“, serving over 160 labs in additional than 30 nations.
“The speedy tempo of personalised medication calls for steady funding in software program innovation and deep specialisation,” mentioned Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class staff, we’re additional enhancing our sturdy progress trajectory and skill to supply market-leading software program to clients, skilled interpretation providers, and deepening our presence within the UK market – a international chief in scientific genomics for the reason that landmark 100,000 Genomes Challenge.”
Based in 2012, Congenica brings scientific experience and expertise servicing over 25 personal and public labs, together with a number of NHS Genomics Laboratory Hubs and nationwide programmes comparable to Genomics England and the Hong Kong Genomic Programme.
Based in 2017, SeqOne is an AI-powered genomic evaluation platform, offering scientific decision-support instruments that allow molecular laboratories to ship quick, correct, and scalable evaluation of genetic knowledge for purposes in oncology, uncommon and inherited ailments, and infectious ailments.
The acquisition unites SeqOne’s AI-powered platform for Subsequent-Technology Sequencing (NGS) evaluation with Congenica’s scientific choice assist expertise and scientific interpretation providers. The built-in providing will rework advanced genomic knowledge into speedy, actionable insights, in the end accelerating analysis for households affected by uncommon illness and enabling extra exact, personalised most cancers therapies.
This transfer comes at a essential inflection level in medication. The price to sequence a human genome has plummeted, creating a knowledge tsunami. For hospitals and labs worldwide, the problem is not producing knowledge, however deciphering it. This ‘interpretation bottleneck’ is reportedly the only largest barrier to delivering personalised medication.
“Congenica has been an instrumental companion to Genomics England, significantly in advancing uncommon illness analysis by way of their sturdy platform for scientific complete genome evaluation,” mentioned Dr Richard Scott, Chief Government Officer at Genomics England. “We look ahead to persevering with this necessary work with the mixed experience of the SeqOne staff to ship advantages for sufferers.”
The acquisition comes on the heels of a interval of intense natural progress for SeqOne, which has seen the corporate reortedly double its income and broaden its worldwide presence from three to over 30 nations in simply 12 months.
It additionally follows the acquisition of Life & Soft in April, which expanded the corporate’s capabilities into multi-omics and virology. This momentum, supercharged by a €20 million funding round, has enabled SeqOne to execute its technique to consolidate a fragmented market and construct the definitive software program working system for the scientific genomics revolution.
The mixed entity may have a considerably expanded international footprint:
- Serving over 160 buyer laboratories in additional than 30 nations.
- Comprising a devoted staff of over 125 staff.
- Enabling over 200,000 affected person genomic analyses in 2025 – a threefold improve over 2024.
SeqOne is dedicated to making sure continuity of service and assist for all Congenica clients, who will acquire entry to an expanded and built-in product portfolio. SeqOne will keep a significant UK presence on the Wellcome Sanger Institute.
“The Board of Congenica is pleased with the immense influence our expertise has had on healthcare since our inception,” mentioned Dr Andy Richards CBE, Chairman of Congenica. “We assist this mix with SeqOne, believing their imaginative and prescient and sources are finest positioned to hold that legacy ahead and guarantee our modern platform continues to thrive and serve sufferers globally.”
